In this episode of Sue Wall Street, Cassie and Bill dive into the spectacular collapse of $ANRO Alto Neuroscience. After raising $119M in its 2024 IPO on hopes of revolutionizing psychiatry, its flagship drug ALTO-100 flunked a critical trial—sending shares plummeting nearly 70%. We unpack the lawsuit alleging misleading IPO documents, dig into the risks of precision medicine, and ask: was this hype or just heartbreak? Perfect for investors, biotech watchers, and anyone tracking Wall Street accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.